A Phase 2 interventional study of GSK1278863 and Placebo in Anemia and Anaemia, sponsored by GlaxoSmithKline. Terminated at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.
Among the 30 studies testing GSK1278863 in Anemia, this one is the 25th largest by enrollment, is one of 3 that started in 2014, is one of 10 in phase 2, and was the 9th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:
GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 76 across the 30 interventional studies. Of the 29 that completed or were terminated, 23 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 30 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Anemia by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 35 finished, 25 (71%) have results posted.
Among the 35 studies in Anemia by GlaxoSmithKline, this one is the 30th largest by enrollment, is one of 3 that started in 2014, is one of 11 in phase 2, and was the 14th registered.
GlaxoSmithKline’s Anemia studies by the year they started, since 2006.
1 of the studies testing GSK1278863 in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07300111Phase 3Qilu Pharmaceutical Co., Ltd.A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing GSK1278863 in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will evaluate the ability of GSK1278863 to increase the hemoglobin (Hgb) concentration, or maintain it within the target range, and the safety and efficacy of GSK1278863 over 16 weeks of treatment, in hemodialysis-dependent subjects with anemia associated with chronic kidney disease who are chronically hyporesponsive to rhEPO. The data generated will inform dose requirements for any chronic rhEPO hyporesponsive hemodialysis-dependent subjects included in future clinical trials. The study consists of a 4-week rhEPO run-in period, a 16-week GSK1278863 treatment period and a 4-week Follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive a fixed starting dose of 12 milligrams (mg) GSK1278863 once daily (QD) orally for first 4 weeks. From Week 4 the dose of GSK1278863 will be adjusted based on Hgb levels and evaluated every 4 weeks until Week 16. This starting dose may be changed during the study if there is an early indication of either lack of efficacy or the rate of rise in Hgb is too rapid
Drug: GSK1278863 · Drug: Placebo
Film coated tablets containing 1 mg, 2 mg, 5 mg or 25 mg of GSK1278863
Matching placebo tablet for GSK1278863
Percentage of Participants Demonstrating an Increase in Hgb of >=1 g/dL (if Baseline Hgb is <9.5 g/dL), or >=0.5 g/dL (if Baseline Hgb is 9.5-<10 g/dL), or Stay Within Target Range and do Not Drop by >0.5 g/dL (if Baseline Hgb is >= 10 g/dL) at Week 16
Percentage of participants with increased Hgb \>=1 g/dL (if baseline Hgb is \<9.5 g/dL), or \>=0.5 g/dL (if baseline Hgb is 9.5-\<10 g/dL), or within the target range and not dropped by \>0.5 g/dL (if baseline Hgb is \>= 10 g/dL) at Week 16 are presented. Participants who were available at the indicated time point were analyzed
Time frame: Week 16
Change From Baseline in Hgb Levels at Week 16
Hgb values measured at Week 16 are presented. Change from baseline was calculated as Week 16 minus baseline value . Participants who were available at the indicated time point were analyzed.
Time frame: Week 16
Percentage of Time (Days) Hgb Levels Within, Below and Above Target Range at the Indicated Time Point
The percentage of time in Hgb levels were in target range (10.0 to 11.5 g/dL) between Weeks 12 and 16 for a participant was calculated by adding the total number of days that Hgb is within target range while on treatment during Weeks 12 to 16 and dividing by the total number of days the participant remained on treatment during Weeks 12 to 16 (using Rosendaal linear interpolation method). Similarly, percentage of time above Hgb target range and percentage of time below Hgb target range were calculated. Participants who were available at the indicated time point were analyzed.
Time frame: Week 12 to Week 16
Number of Participants Achieving at Least 1 g/dL Increase in Hgb From Baseline at Week 16
Number of participants achieving at least 1 g/dL increase in Hgb from baseline at Week 16 were presented. Participants who were available at the indicated time point were analyzed.
Time frame: Baseline and Week 16
Number of Participants With Hgb in the Target Range at Week 16
The number of participants with Hgb in the target range of 10.0 to 11.5 g/dL at Week 16 were analyzed. Participants who were available at the indicated time point were analyzed.
Time frame: Week 16
Number of Participants Reaching Pre-defined Hgb Stopping Criteria
The number of participants who reached the Hgb stopping criteria of Hgb concentration \<7.5 g/dL from baseline to Week 16 were presented. Participants who were available at the indicated time point were analyzed.
Time frame: Up to Week 16
Percent Change From Baseline in Hepcidin at Week 16
Hepcidin is a regulator of iron metabolism. Baseline value for hepcidin is the pre-dose value on Day 1. Percent change was calculated as 100 multiplied by \[exponential (log Week 16 value - log Baseline value) minus 1\]. Participants who were available at the indicated time point were analyzed.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in Ferritin at Week 16
Baseline value for ferritin is the last pre-dose value on Day 1. Change from Baseline in ferritin was calculated as the Week 16 value minus the Baseline value. Participants who were available at the indicated time point were analyzed.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in Transferrin at Week 16
Baseline value for transferrin is the last pre-dose value on Day 1. Change from Baseline in transferrin was calculated as the Week 16 value minus the Baseline value. Participants who were available at the indicated time point were analyzed.
Time frame: Baseline (Day 1) and Week 16
Percent Change From Baseline in Transferrin Saturation at Week 16
Transferrin saturation is measured in percentage, it is the ratio of serum iron and total iron-binding capacity, multiplied by 100. Baseline value for transferrin saturation is the pre-dose value on Day 1. Percent change is 100 times \[exponential (log Week 16 value minus log Baseline value) -1\]. Participants who were available at the indicated time point were analyzed.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in Total Iron at Week 16
Baseline value for total iron is the last pre-dose value on Day 1. Change from Baseline in total iron was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in Total Iron Binding Capacity (TIBC) at Week 16
Total iron-binding capacity is a medical laboratory test that measures the blood's capacity to bind iron with transferrin. Baseline value for total iron binding capacity is the last pre-dose value on Day 1. Change from Baseline in total iron binding capacity was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points.
Time frame: Baseline (Day 1) and Week 16
Reticulocyte Hgb Content (CHr) at Week 16
Data has been presented for only those participants who were available at indicated timepoints
Time frame: Week 16
Mean Corpuscular Volume (MCV) at Week 16
Data has been presented for only those participants who were available at indicated time points.
Time frame: Week 16
Mean Corpuscular Hemoglobin (MCH) at Week 16
Data has been presented for only those participants who were available at indicated time points.
Time frame: Week 16
Change From Baseline in Hematocrit at Week 16
Hematocrit is the ratio of the volume of red blood cells to the total volume of blood. Baseline value for hematocrit is the pre-dose value on Day 1. Change from Baseline in hematocrit was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in Red Blood Cell (RBC) at Week 16
Baseline value for RBC (or erythrocytes) is the last pre-dose value on Day 1. Change from Baseline in red blood cells was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in Reticulocyte Number at Week 16
Baseline value for reticulocyte number is the pre-dose value on Day 1. Change from Baseline in reticulocyte number was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points.
Time frame: Baseline (Day 1) and Week 16
Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)
Blood samples were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose, then 1, 2 and 3 hours after first sample), Week 8 (pre-dose), Week 12 (pre-dose and 3 hour post-dose) and Week 16 (pre-dose) for VEGF measurement. The maximum observed percent change from Baseline in VEGF in the subjects was reported. Baseline value for VEGF is the last pre-dose value on Day 1. Percent change was calculated as 100 multiplied by exponential (log observed maximum value minus log Baseline value) minus 1. Participants who were available at the indicated time point were analyzed.
Time frame: Baseline (Day 1) to Week 16
Maximum Observed Change From Baseline in Erythropoietin (EPO)
Blood samples were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose, then 1, 2 and 3 hours after first sample), Week 8 (pre-dose), Week 12 (pre-dose and 3 hour post-dose) and Week 16 (pre-dose) for EPO measurement. The maximum observed change from baseline in EPO was reported. Baseline value for EPO is the last pre-dose value on Day 1. Change from baseline is calculated as the maximum observed value minus the baseline value. Participants who were available at the indicated time point were analyzed.
Time frame: Baseline (Day 1) to Week 16
Final Dose of GSK1278863
For the first 4 weeks, subjects received 12mg QD of GSK1278863 with dose decrease permitted at Week 2. After 4 weeks of treatment with GSK1278863, need for dose adjustment was evaluated at visits 4, 8 and 12, to maintain hemoglobin within the target range. Target range was defined as: Hgb Criteria of 10.0 to 11.5 g/dL. Data has been presented for only those participants who were available at indicated time points.
Time frame: Up to 16 Weeks
Plasma Concentrations of GSK1278863 and Its Metabolites at the Indicated Time Points
Blood samples were collected for individual plasma GSK1278863and metabolite (GSK2391220, GSK2499166, GSK2531403, GSK2531400, GSK2531399, and GSK2531398) concentrations measurement on Day (D) 1 (pre-dose \[PrD\]), at Week (W) 4 (6-12, 7-13, 8-14, and 9-15 hour \[hr\] post-dose \[PoD), and at W12 (PrD, 1, 2, and 3 hour PoD). Pharmacokinetic population: All participants from whom a PK sample has been obtained and analyzed.
Time frame: Day 1, Week 4 and Week 12
Eligible hemodialysis-dependent participants (par.) with anemia associated with chronic kidney disease and chronically hyporesponsive to recombinant human erythropoietin (rhEPO) (for 12 weeks) were switched from a stable dose of rhEPO
| Milestone | GSK1278863 12 mg QD |
|---|---|
| Started | 15 |
| Completed | 7 |
| Not completed | 8 |
| Withdrew: Adverse event | 3 |
| Withdrew: Par. reached stopping criteria | 4 |
| Withdrew: Withdrawal by subject | 1 |
Percentage of participants with increased Hgb \>=1 g/dL (if baseline Hgb is \<9.5 g/dL), or \>=0.5 g/dL (if baseline Hgb is 9.5-\<10 g/dL), or within the target range and not dropped by \>0.5 g/dL (if baseline Hgb is \>= 10 g/dL) at Week 16 are presented. Participants who were available at the indicated time point were analyzed
| Percentage of participants | GSK1278863 12 mg QD |
|---|---|
| Percentage of Participants Demonstrating an Increase in Hgb of >=1 g/dL (if Baseline Hgb is <9.5 g/dL), or >=0.5 g/dL (if Baseline Hgb is 9.5-<10 g/dL), or Stay Within Target Range and do Not Drop by >0.5 g/dL (if Baseline Hgb is >= 10 g/dL) at Week 16 | 28.6 (8.2 to 64.1) |
Hgb values measured at Week 16 are presented. Change from baseline was calculated as Week 16 minus baseline value . Participants who were available at the indicated time point were analyzed.
| g/dL | GSK1278863 12 mg QD |
|---|---|
| Change From Baseline in Hgb Levels at Week 16 | 0.10 ± 1.319 |
The percentage of time in Hgb levels were in target range (10.0 to 11.5 g/dL) between Weeks 12 and 16 for a participant was calculated by adding the total number of days that Hgb is within target range while on treatment during Weeks 12 to 16 and dividing by the total number of days the participant remained on treatment during Weeks 12 to 16 (using Rosendaal linear interpolation method). Similarly, percentage of time above Hgb target range and percentage of time below Hgb target range were calculated. Participants who were available at the indicated time point were analyzed.
| Percentage of days | GSK1278863 12 mg QD |
|---|---|
| Within Target Range | 48.28 ± 46.102 |
| Above target range | 0.92 ± 2.605 |
| Below target range | 50.80 ± 47.176 |
Number of participants achieving at least 1 g/dL increase in Hgb from baseline at Week 16 were presented. Participants who were available at the indicated time point were analyzed.
| Participants | GSK1278863 12 mg QD |
|---|---|
| Number of Participants Achieving at Least 1 g/dL Increase in Hgb From Baseline at Week 16 | 2 |
The number of participants with Hgb in the target range of 10.0 to 11.5 g/dL at Week 16 were analyzed. Participants who were available at the indicated time point were analyzed.
| Participants | GSK1278863 12 mg QD |
|---|---|
| Number of Participants With Hgb in the Target Range at Week 16 | 2 |
The number of participants who reached the Hgb stopping criteria of Hgb concentration \<7.5 g/dL from baseline to Week 16 were presented. Participants who were available at the indicated time point were analyzed.
| Participants | GSK1278863 12 mg QD |
|---|---|
| Number of Participants Reaching Pre-defined Hgb Stopping Criteria | 3 |
Hepcidin is a regulator of iron metabolism. Baseline value for hepcidin is the pre-dose value on Day 1. Percent change was calculated as 100 multiplied by \[exponential (log Week 16 value - log Baseline value) minus 1\]. Participants who were available at the indicated time point were analyzed.
| Percent change in hepcidin | GSK1278863 12 mg QD |
|---|---|
| Percent Change From Baseline in Hepcidin at Week 16 | 16.49 (-12.14 to 54.43) |
Baseline value for ferritin is the last pre-dose value on Day 1. Change from Baseline in ferritin was calculated as the Week 16 value minus the Baseline value. Participants who were available at the indicated time point were analyzed.
| Micrograms/Liter | GSK1278863 12 mg QD |
|---|---|
| Change From Baseline in Ferritin at Week 16 | -72.1 ± 134.81 |
Baseline value for transferrin is the last pre-dose value on Day 1. Change from Baseline in transferrin was calculated as the Week 16 value minus the Baseline value. Participants who were available at the indicated time point were analyzed.
| Percent change | GSK1278863 12 mg QD |
|---|---|
| Change From Baseline in Transferrin at Week 16 | 0.080 ± 0.2332 |
Transferrin saturation is measured in percentage, it is the ratio of serum iron and total iron-binding capacity, multiplied by 100. Baseline value for transferrin saturation is the pre-dose value on Day 1. Percent change is 100 times \[exponential (log Week 16 value minus log Baseline value) -1\]. Participants who were available at the indicated time point were analyzed.
| Percent change in transferrin | GSK1278863 12 mg QD |
|---|---|
| Percent Change From Baseline in Transferrin Saturation at Week 16 | 18.5 (-21.4 to 78.8) |
Baseline value for total iron is the last pre-dose value on Day 1. Change from Baseline in total iron was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points.
| Micromoles (µmol)/L | GSK1278863 12 mg QD |
|---|---|
| Participant 1 | 4 |
| Participant 2 | 21 |
| Participant 3 | -3 |
| Participant 4 | 3 |
| Participant 5 | 2 |
| Participant 6 | 5 |
| Participant 7 | -5 |
Total iron-binding capacity is a medical laboratory test that measures the blood's capacity to bind iron with transferrin. Baseline value for total iron binding capacity is the last pre-dose value on Day 1. Change from Baseline in total iron binding capacity was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points.
| µmol/ L | GSK1278863 12 mg QD |
|---|---|
| Participant 1 | 14 |
| Participant 2 | 12 |
| Participant 3 | -6 |
| Participant 4 | -1 |
| Participant 5 | 6 |
| Participant 6 | -4 |
| Participant 7 | 8 |
Data has been presented for only those participants who were available at indicated timepoints
| Picogram (pg) | GSK1278863 12 mg QD |
|---|---|
| Participant 1 | 38.80 |
| Participant 2 | 31.50 |
| Participant 3 | 32.80 |
| Participant 4 | 30.20 |
| Participant 5 | 31.70 |
| Participant 6 | 30.10 |
| Participant 7 | 34.30 |
Data has been presented for only those participants who were available at indicated time points.
| Femtoliter (fL) | GSK1278863 12 mg QD |
|---|---|
| Participant 1 | 124.00 |
| Participant 2 | 99.00 |
| Participant 3 | 97.00 |
| Participant 4 | 101.00 |
| Participant 5 | 94.00 |
| Participant 6 | 97.00 |
| Participant 7 | 106.00 |
Data has been presented for only those participants who were available at indicated time points.
| pg | GSK1278863 12 mg QD |
|---|---|
| Participant 1 | 39.80 |
| Participant 2 | 31.30 |
| Participant 3 | 31.70 |
| Participant 4 | 31.60 |
| Participant 5 | 30.90 |
| Participant 6 | 30.70 |
| Participant 7 | 35.70 |
Hematocrit is the ratio of the volume of red blood cells to the total volume of blood. Baseline value for hematocrit is the pre-dose value on Day 1. Change from Baseline in hematocrit was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points.
| Fraction of 1 | GSK1278863 12 mg QD |
|---|---|
| Participant 1 | -0.025 |
| Participant 2 | 0.067 |
| Participant 3 | -0.015 |
| Participant 4 | 0.043 |
| Participant 5 | -0.016 |
| Participant 6 | 0.004 |
| Participant 7 | -0.089 |
Baseline value for RBC (or erythrocytes) is the last pre-dose value on Day 1. Change from Baseline in red blood cells was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points
| 10^12/L | GSK1278863 12 mg QD |
|---|---|
| Participant 1 | -0.3 |
| Participant 2 | 0.7 |
| Participant 3 | -0.1 |
| Participant 4 | 0.3 |
| Participant 5 | -0.1 |
| Participant 6 | 0.2 |
| Participant 7 | -0.7 |
Baseline value for reticulocyte number is the pre-dose value on Day 1. Change from Baseline in reticulocyte number was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points.
| 10^12/L | GSK1278863 12 mg QD |
|---|---|
| Participant 1 | 0.0003 |
| Participant 2 | 0.0043 |
| Participant 3 | -0.0174 |
| Participant 4 | -0.0139 |
| Participant 5 | -0.0201 |
| Participant 6 | -0.0458 |
| Participant 7 | -0.0006 |
Blood samples were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose, then 1, 2 and 3 hours after first sample), Week 8 (pre-dose), Week 12 (pre-dose and 3 hour post-dose) and Week 16 (pre-dose) for VEGF measurement. The maximum observed percent change from Baseline in VEGF in the subjects was reported. Baseline value for VEGF is the last pre-dose value on Day 1. Percent change was calculated as 100 multiplied by exponential (log observed maximum value minus log Baseline value) minus 1. Participants who were available at the indicated time point were analyzed.
| Percent change | GSK1278863 12 mg QD |
|---|---|
| Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF) | 58.72 (35.56 to 85.84) |
Blood samples were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose, then 1, 2 and 3 hours after first sample), Week 8 (pre-dose), Week 12 (pre-dose and 3 hour post-dose) and Week 16 (pre-dose) for EPO measurement. The maximum observed change from baseline in EPO was reported. Baseline value for EPO is the last pre-dose value on Day 1. Change from baseline is calculated as the maximum observed value minus the baseline value. Participants who were available at the indicated time point were analyzed.
| international units(IU)/Liter (L) | GSK1278863 12 mg QD |
|---|---|
| Maximum Observed Change From Baseline in Erythropoietin (EPO) | 253.07 ± 526.670 |
For the first 4 weeks, subjects received 12mg QD of GSK1278863 with dose decrease permitted at Week 2. After 4 weeks of treatment with GSK1278863, need for dose adjustment was evaluated at visits 4, 8 and 12, to maintain hemoglobin within the target range. Target range was defined as: Hgb Criteria of 10.0 to 11.5 g/dL. Data has been presented for only those participants who were available at indicated time points.
| mg | GSK1278863 12 mg QD |
|---|---|
| Participant 1 | 25 |
| Participant 2 | 12 |
| Participant 3 | 25 |
| Participant 4 | 8 |
| Participant 5 | 12 |
| Participant 6 | 15 |
| Participant 7 | 10 |
| Participant 8 | 12 |
| Participant 9 | 0 |
| Participant 10 | 12 |
| Participant 11 | 12 |
| Participant 12 | 15 |
| Participant 13 | 15 |
| Participant 14 | 15 |
| Participant 15 | 25 |
Blood samples were collected for individual plasma GSK1278863and metabolite (GSK2391220, GSK2499166, GSK2531403, GSK2531400, GSK2531399, and GSK2531398) concentrations measurement on Day (D) 1 (pre-dose \[PrD\]), at Week (W) 4 (6-12, 7-13, 8-14, and 9-15 hour \[hr\] post-dose \[PoD), and at W12 (PrD, 1, 2, and 3 hour PoD). Pharmacokinetic population: All participants from whom a PK sample has been obtained and analyzed.
| ng/mL | GSK1278863 12 mg QD |
|---|---|
| GSK1278863, D1, PrD, n=15 | 0 ± 0 |
| GSK1278863, W4, 6-12 hr PoD, n=13 | 64.8 ± 166.48 |
| GSK1278863, W4, 7-13 hr PoD, n=13 | 88.6 ± 213.55 |
| GSK1278863, W4, 8-14 hr PoD, n=13 | 79 ± 204.25 |
| GSK1278863, W4, 9-15 hr PoD, n=13 | 67.4 ± 186.84 |
| GSK1278863, W12, PrD, n=8 | 18 ± 34.15 |
| GSK1278863, W12, 0.5-1 hr PoD, n=8 | 125 ± 186.65 |
| GSK1278863, W12, 2 hr PoD, n=8 | 103.7 ± 140.78 |
| GSK1278863, W12, 3 hr PoD, n=8 | 40.6 ± 32.53 |
| GSK2391220, D1, PrD, n=15 | 0 ± 0 |
| GSK2391220, W4, 6-12 hr PoD, n=13 | 41.3 ± 19.16 |
| GSK2391220, W4, 7-13 hr PoD, n=13 | 22.6 ± 10 |
| GSK2391220, W4, 8-14 hr PoD, n=13 | 16.7 ± 8.03 |
| GSK2391220, W4, 9-15 hr PoD, n=13 | 12.9 ± 6.95 |
| GSK2391220, W12, PrD, n=8 | 25.9 ± 22.79 |
| GSK2391220, W12, 0.5-1 hr PoD, n=8 | 24.9 ± 21.63 |
| GSK2391220, W12, 2 hr PoD, n=8 | 23.7 ± 19.94 |
| GSK2391220, W12, 3 hr PoD, n=8 | 18 ± 13.43 |
| GSK2487818, D1, PrD, n=15 | 0 ± 0 |
| GSK2487818, W4, 6-12 hr PoD, n=13 | 15.8 ± 11.02 |
| GSK2487818, W4, 7-13 hr PoD, n=13 | 9.3 ± 6.1 |
| GSK2487818, W4, 8-14 hr PoD, n=13 | 7.2 ± 4.96 |
| GSK2487818, W4, 9-15 hr PoD, n=13 | 5.8 ± 4.97 |
| GSK2487818, W12, PrD, n=8 | 6.5 ± 9.01 |
| GSK2487818, W12, 0.5-1 hr PoD, n=8 | 10.6 ± 10.87 |
| GSK2487818, W12, 2 hr PoD, n=8 | 15.6 ± 19.22 |
| GSK2487818, W12, 3 hr PoD, n=8 | 11.6 ± 11.17 |
| GSK2506102, D1, PrD, n=15 | 0 ± 0 |
| GSK2506102, W4, 6-12 hr PoD, n=13 | 13.6 ± 6.55 |
| GSK2506102, W4, 7-13 hr PoD, n=13 | 7.5 ± 3.34 |
| GSK2506102, W4, 8-14 hr PoD, n=13 | 5.6 ± 2.6 |
| GSK2506102, W4, 9-15 hr PoD, n=13 | 4.3 ± 2.24 |
| GSK2506102, W12, PrD, n=8 | 10 ± 7.54 |
| GSK2506102, W12, 0.5-1 hr PoD, n=8 | 7.9 ± 6.53 |
| GSK2506102, W12, 2 hr PoD, n=8 | 6.3 ± 4.14 |
| GSK2506102, W12, 3 hr PoD, n=8 | 4.9 ± 3.2 |
| GSK2531398, D1, PrD, n=15 | 0 ± 0 |
| GSK2531398, W4, 6-12 hr PoD, n=13 | 16.6 ± 9.12 |
| GSK2531398, W4, 7-13 hr PoD, n=13 | 9.4 ± 4.98 |
| GSK2531398, W4, 8-14 hr PoD, n=13 | 7.1 ± 4.04 |
| GSK2531398, W4, 9-15 hr PoD, n=13 | 5.6 ± 3.5 |
| GSK2531398, W12, PrD, n=8 | 8.2 ± 7.78 |
| GSK2531398, W12, 0.5-1 hr PoD, n=8 | 8.5 ± 7.57 |
| GSK2531398, W12, 2 hr PoD, n=8 | 9.3 ± 8.71 |
| GSK2531398, W12, 3 hr PoD, n=8 | 7.3 ± 5.75 |
| GSK2531401, D1, PrD, n=15 | 0 ± 0 |
| GSK2531401, W4, 6-12 hr PoD, n=13 | 28.4 ± 11.94 |
| GSK2531401, W4, 7-13 hr PoD, n=13 | 15.6 ± 5.64 |
| GSK2531401, W4, 8-14 hr PoD, n=13 | 11.6 ± 4.43 |
| GSK2531401, W4, 9-15 hr PoD, n=13 | 8.7 ± 3.22 |
| GSK2531401, W12, PrD, n=8 | 27.8 ± 22.34 |
| GSK2531401, W12, 0.5-1 hr PoD, n=8 | 21 ± 19.46 |
| GSK2531401, W12, 2 hr PoD, n=8 | 14.6 ± 11.05 |
| GSK2531401, W12, 3 hr PoD, n=8 | 11.2 ± 8.83 |
| GSK2531403, D1, PrD, n=15 | 0 ± 0 |
| GSK2531403, W4, 6-12 hr PoD, n=13 | 51.8 ± 22.75 |
| GSK2531403, W4, 7-13 hr PoD, n=13 | 28.2 ± 11.85 |
| GSK2531403, W4, 8-14 hr PoD, n=13 | 20.6 ± 9.34 |
| GSK2531403, W4, 9-15 hr PoD, n=13 | 15.8 ± 8.07 |
| GSK2531403, W12, PrD, n=8 | 35.8 ± 28.09 |
| GSK2531403, W12, 0.5-1 hr PoD, n=8 | 30.6 ± 25.2 |
| GSK2531403, W12, 2 hr PoD, n=8 | 25.7 ± 18.15 |
| GSK2531403, W12, 3 hr PoD, n=8 | 19.6 ± 13.14 |
Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study treatment and until the follow up (up to 20 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK1278863 12 mg QD | — | 9/15 (60%) | 11/15 (73.3%) |
| Event | GSK1278863 12 mg QD |
|---|---|
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 1/15 |
| ANGINA UNSTABLECardiac disorders | 1/15 |
| CARDIAC ARRESTCardiac disorders | 1/15 |
| VENTRICULAR TACHYCARDIACardiac disorders | 1/15 |
| GASTROENTERITIS VIRALInfections and infestations | 1/15 |
| PNEUMONIAInfections and infestations | 1/15 |
| PNEUMONIA MYCOPLASMALInfections and infestations | 1/15 |
| GASTROINTESTINAL STOMA COMPLICATIONInjury, poisoning and procedural complications | 1/15 |
| PROCEDURAL HAEMORRHAGEInjury, poisoning and procedural complications | 1/15 |
| HAEMATOMAVascular disorders | 1/15 |
| Event | GSK1278863 12 mg QD |
|---|---|
| NAUSEAGastrointestinal disorders | 3/15 |
| URINARY TRACT INFECTIONInfections and infestations | 2/15 |
| PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders | 2/15 |
| GASTROENTERITIS VIRALInfections and infestations | 1/15 |
| INFLUENZAInfections and infestations | 1/15 |
| PNEUMONIAInfections and infestations | 1/15 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 1/15 |
| VOMITINGGastrointestinal disorders | 1/15 |
| BLOOD CALCIUM DECREASEDInvestigations | 1/15 |
| BLOOD PRESSURE INCREASEDInvestigations | 1/15 |
| Age, Continuous(Years) | GSK1278863 12 mg QD |
|---|---|
| Mean | 59.1 ± 12.76 |
| Sex: Female, Male(Participants) | GSK1278863 12 mg QD |
|---|---|
| Female | 7 |
| Male | 8 |
| Race/Ethnicity, Customized(Participants) | GSK1278863 12 mg QD |
|---|---|
| BLACK OR AFRICAN AMERICAN | 2 |
| WHITE | 13 |
Ran from Jun 2014 to primary completion in Mar 2016, 21 months.
Results were first posted in Jun 2017, 1 year 3 months after primary completion. A results delay was requested in Aug 2016.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK1278863